Table 3.
Odds ratios (ORs) for breast cancer associated with a doubling in concentrations of hormones and SHBG, subdivided by oestrogen receptor status
| ER positive | ER negative | ||||
|---|---|---|---|---|---|
| Hormone | Cases/controls | OR (95% CI) | Cases/controls | OR (95% CI) | P for heterogeneity |
| Oestradiol | 147/374 | 1.25 (0.95–1.65) | 71/209 | 1.09 (0.76–1.57) | 0.56 |
| Calculated free oestradiol | 147/374 | 1.22 (0.91–1.63) | 71/209 | 1.03 (0.68–1.54) | 0.50 |
| Oestrone | 107/205 | 1.26 (0.77–2.06) | 37/72 | 0.90 (0.45–1.82) | 0.45 |
| Luteal phase progesterone | 152/369 | 1.05 (0.88–1.24) | 67/184 | 1.13 (0.88–1.47) | 0.62 |
| Androstenedione | 124/237 | 1.45 (0.98–2.15) | 54/106 | 1.11 (0.58–2.14) | 0.50 |
| DHEAS | 170/327 | 1.24 (0.97–1.57) | 67/130 | 0.91 (0.62–1.34) | 0.19 |
| Testosterone | 211/495 | 1.13 (0.88–1.43) | 99/265 | 1.03 (0.76–1.39) | 0.66 |
| Calculated free testosterone | 211/495 | 1.08 (0.88–1.33) | 99/264 | 1.01 (0.78–1.30) | 0.66 |
| SHBG | 214/503 | 1.04 (0.80–1.35) | 102/271 | 1.08 (0.77–1.52) | 0.86 |
Estimates are from conditional logistic regression on case-control sets matched within each study and adjusted for phase of menstrual cycle at blood collection within study.